1. 1-24 of 24
    1. Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

      Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

      e/ -- Micell Technologies, Inc . announced completion of enrollment in the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study. The study will compare changes in coronary arteries between six and 24 months following treatment with MiStent or XIENCE V Everolimus Eluting Coronary Stent System (Xience). The clinical investigation and data analysis are being conducted by Cardialysis and the European Cardiovascular Research Institute (ECRI), in Rotterdam, The Netherlands. The OCT study will evaluate 60 patients randomized to MiStent or Xience. A prior MiStent clinical study has shown essentially no increase in late lumen loss between ...

      Read Full Article
    2. Frost & Sullivan Recognizes Best-in-class Companies with Prestigious Awards

      Frost & Sullivan Recognizes Best-in-class Companies with Prestigious Awards

      Frost & Sullivan honored recipients of its 2016 Excellence in Best Practices Awards at a gala held Wednesday, January 13, in San Diego, Calif., at the Hilton San Diego Resort & Spa. With a festive ambiance and exciting Awards, the event brought together top executives to celebrate their success. The Awards gala was preceded by a 90-minute Frost & Sullivan Demand & Brand Workshop, designed exclusively for company leaders seeking to grow their brand recognition... Bioptigen, Inc. – 2015 North American Ophthalmic Imaging Technology Leadership Award

      Read Full Article
    3. MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors

      MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors

      MedLumics , a cardiology device company specializing in the application of advanced optical coherence tomography (OCT) technology, has announced the appointment of cardiovascular device veteran Tim Lenihan to its board of directors. With vast experience in field of electrophysiology, Lenihan will help guide the continued advancement of the company’s catheter ablation technology for the treatment of atrial fibrillation. “We are very fortunate to add Tim to our board of directors given his domain expertise in catheter-based medical technologies, specifically in the cardiac ablation field,” said Eduardo Margallo, CEO of MedLumics. “His experience and insights will undoubtedly make an enormous contribution ...

      Read Full Article
    4. Optovue Showcases Total Cornea Power for Better Eyesight After Cataract Surgery at AAO 2015

      Optovue Showcases Total Cornea Power for Better Eyesight After Cataract Surgery at AAO 2015

      Optovue, the global leader in the clinical development and commercialization of optical coherence tomography angiography (OCTA), today announced that it will showcase several advanced technologies at AAO 2015, the 119 th annual meeting of the American Academy of Ophthalmology, being held in Las Vegas from November 14-17. Total Cornea Power (TCP™) and the AngioVue™* Imaging System with AngioAnalytics™*, are designed to improve disease and procedure management, which may lead to improved outcomes for patients with sight-threatening diseases

      Read Full Article
    5. MedTech's Partial Tax Repeal: Is It Enough?

      MedTech's Partial Tax Repeal: Is It Enough?

      The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax since its enactment in the beginning of 2013. Sequestration-related spending cuts to the U.S. federal budget have also undermined the medical devices industry’s prospects. In fact, this has significantly restricted the industry’s bottom-line improvement in the past year.

      Read Full Article
    6. St. Jude Medical to Showcase PCI Optimization Technology and Structural Heart Portfolio at EuroPCR

      St. Jude Medical to Showcase PCI Optimization Technology and Structural Heart Portfolio at EuroPCR
      ST. PAUL, Minn.--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ - News), a global medical device company, today announced products on display, sponsorship of several percutaneous coronary intervention (PCI) optimization symposia and reporting of results from an economic analysis during a late breaking trial session at the Paris Course on Revascularization (EuroPCR) 2011. The focus on clinical research and new product development reflects the company’s commitment to provide physicians with innovative solutions that demonstrate a tangible benefit to patients and society. “With new technologies in PCI optimization and programs across all major structural heart categories, the St. Jude Medical ...
      Read Full Article
    7. Medical Devices Industry Outlook

      Medical Devices Industry Outlook
      Intravascular ultrasound imaging (IVUS), Optical Coherence Tomography (OCT) and other next-generation imaging technologies are expected to offer incremental opportunity for the incumbent players such as Volcano Corp. (NasdaqGS: VOLC - News), Boston Scientific and St. Jude. The OCT market has been projected to grow at a double-digit rate over the next five years. We believe that emerging markets represent a key catalyst for growth in 2011 and beyond.
      Read Full Article
    8. Bioengineering Applications in Performing Arts and Entertainment Industry Conference and XIX Pacific Voice Conference at Santa Clara University to Tackle the Human Voice

      Bioengineering Applications in Performing Arts and Entertainment Industry Conference and XIX Pacific Voice Conference at Santa Clara University to Tackle the Human Voice
      The human voice has an amazing range of sounds that can evoke an even greater gamut of emotions. But how do the vocal cords actually produce the sound? How does the surrounding environment affect the voice? How can singers, musicians and performers protect them to produce a healthier and a better sounding voice? The sessions include: Technology for Vocal Cords Imaging: High Speed Digital Imaging, Electroglottography, Optical Coherence Tomography
      Read Full Article
    9. ROTH Capital Partners to Host 23rd Annual OC Growth Stock Conference March 13-16, 2011

      ROTH Capital Partners to Host 23rd Annual OC Growth Stock Conference March 13-16, 2011
      NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- ROTH Capital Partners (ROTH), www.roth.com, an investment bank recognized for providing financing and advisory services to emerging growth companies, today announced that their 23rd Annual OC Growth Stock Conference will be held March 13-16, 2011 at The Ritz Carlton, located at 1 Ritz Carlton Drive, Dana Point, California. The three-day, institutional investor conference will feature management presentations from over 400 small-cap public companies--100 of which are based in China, will be the largest ROTH conference to date. The presenting companies represent a broad spectrum of sectors, including: Business Services, Cleantech, Enterprise Software, Gaming ...
      Read Full Article
    10. Volcano Tops, Raises EPS Outlook

      Volcano Tops, Raises EPS Outlook
      Volcano Corporation (NasdaqGS: VOLC - News) reported an EPS of 10 cents in the third quarter of fiscal 2010, surpassing the year-ago quarter’s adjusted net loss per share of 5 cents and the Zacks Consensus Estimate of 1 cent. Revenues increased 35.3% annually to reach $72.9 million with strong growth in Intravascular Ultrasound (IVUS) and Functional Measurement (FM) single-procedure disposables. Revenues were higher than the Zacks Consensus Estimate of $71 million
      Read Full Article
    11. Earnings Scorecard: St. Jude

      Earnings Scorecard: St. Jude
      Minnesota-based medical devices major St. Jude Medical (NYSE: STJ - News) produced a mixed bag in the third quarter beating earnings expectations, but missing on the revenue front. Adjusted earnings of 72 cents per share topped the Zacks Consensus Estimate of 68 cents (representing a 5.88% positive surprise) while net income zoomed roughly 25%, buoyed by revenue growth across the board. Revenues rose 7% year-over-year to $1,240 million, but trailed the Zacks Consensus Estimate of $1,247 million. Growth was led by healthy ICD sales which spiked 13% to $439 million. However, the encouraging ICD growth, by some measure ...
      Read Full Article
      Mentions: St. Jude Medical
    12. Large Healthcare Track Featured at Roth Capital Partners 22nd Annual OC Growth Stock Conference March 15-17, 2010

      NEWPORT BEACH, Calif.----ROTH Capital Partners , www.roth.com, a full service investment bank recognized for providing financing and advisory services to emerging growth companies worldwide, today announced that the upcoming 22nd Annual OC Growth Stock Conference will include a healthcare track featuring the management teams from over 100 healthcare companies.
      Read Full Article
    13. Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract Thrombus Aspiration Catheter

      Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract Thrombus Aspiration Catheter
      SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical. Volcano became the exclusive global distributor of the Xtract™ catheter in May 2009. This acquisition reinforces Volcano's dedication to build a strategic portfolio of diagnostic and therapeutic tools to help patients with coronary artery disease at all levels of complexity, including acute myocardial infarction (AMI) or heart attacks.
      Read Full Article
    14. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines

      Volcano Corporation , a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention , a procedure that treats narrowed blood vessels.
      Read Full Article
    15. Research and Markets: Europe Ophthalmic Devices Investment Opportunities, Analysis and Future Forecasts Through to 2015

      DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0d997e/europe_ophthalmic) has announced the addition of Global Markets Direct's new report "Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015" to their offering. This report is an essential source for in-depth information and data relating to Europe ophthalmic devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the ophthalmic devices market in Europe
      Read Full Article
    16. Michelson Diagnostics Awarded CE-Mark for Clinical Use of Its VivoSight OCT Scanner in Europe and for Non-Clinical Applications Worldwide

      Michelson's Proprietary Multi-Beam OCT Scanner Provides Detailed Images of Sub-Surface Skin Microstructure At Resolutions Currently Out of Reach of Ultrasound and MRI. Michelson Diagnostics has announced the award of a CE-mark for its new VivoSight Optical Coherence Tomography (OCT) scanner, confirming its compliance with the European Medical Device Directive. The CE-Mark approval enables clinical use of the product in Europe and non-clinical use of the product worldwide. In addition, the company has been awarded IS0-13485 status, which enables Michelson to manufacture and sell medical products in Europe. Martin Johns, Operations Director and Quality Representative for Michelson Diagnostics Ltd., said ...
      Read Full Article
    17. Carl Zeiss Meditec Receives FDA Clearance for Cirrus HD-OCT Software Version 4.0

      DUBLIN, Calif.--(BUSINESS WIRE)--A new suite of optical coherence tomography (OCT) software applications for the Cirrus™ HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution. The Cirrus HD-OCT 4.0 with Retinal Nerve Fiber Layer and Macular Normative Databases is indicated for in-vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures. “Throughout our 15 year history of OCT innovation, we have seen its utility evolve from imaging of the retina to now offering both posterior and anterior capabilities,” said Michael Kaschke, PhD, President and Chief Executive ...
      Read Full Article
    18. LightLab Imaging Introduces World's Highest Resolution OCT System for Intracoronary Imaging at EuroPCR 2009

      LightLab Imaging Inc., the pioneer and leader in the development of Optical Coherence Tomography for vascular and other applications, today announced the launch of its next-generation system, the C7XR FD-OCT Imaging System with the C7 Dragonfly Imaging Catheter, at EuroPCR 2009, Barcelona, Spain, solidifying the company's leadership in the intracoronary OCT imaging product market.
      Read Full Article
    19. Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications

      Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications
      MOUNTAIN VIEW, Calif., March 31 /PRNewswire/ -- Based on its recent analysis of the optical technologies market, Frost & Sullivan recognizes Carl Zeiss Meditec with the 2009 North American Frost & Sullivan Market Leadership Award for its optical coherence tomography (OCT) technology for ophthalmic applications. Carl Zeiss Meditec is a pioneer of OCT technology and has launched clinical tools that revolutionized the diagnosis and treatment of eye diseases.
      Read Full Article
    20. Lantis Signs Exclusive Rights in Dentistry for Novel Light-Based Diagnostic Screening Technology

      Lantis Signs Exclusive Rights in Dentistry for Novel Light-Based Diagnostic Screening Technology
      DENVILLE, N.J., March 17, 2009 (GLOBE NEWSWIRE) -- Lantis Laser Inc. (Other OTC:LLSR.PK - News) (http://www.lantislaser.com) today announced that it has signed an exclusive Agreement for the field of human and animal dentistry with the Regents of the University of California for a light-based technology referred to as ``Near-infrared Transillumination Imaging of Early Dental Decay.'' The technology (``NIR Imaging'') is the subject of a PCT patent pending application and was researched and developed over the past five years under the direction of Daniel Fried, PhD, a professor of Biomaterials and Bioengineering in the Department of Preventive ...
      Read Full Article
    21. Lantis Laser CEO to Appear On AOL Finance Small Cap Show Produced by Agoracom

      Lantis Laser CEO to Appear On AOL Finance Small Cap Show Produced by Agoracom
      DENVILLE, N.J., March 11, 2009 (GLOBE NEWSWIRE) -- Lantis Laser Inc. (Other OTC:LLSR.PK - News) (http://www.lantislaser.com), announced today that its President & CEO, Mr. Stan Baron, can be heard all this week on the AOL Small Cap Show produced by AGORACOM Investor Relations. Mr. Baron will be discussing the company's latest developments including making the transition from the Pink Sheets to the OTCBB; the timing of commercial rollout of its OCT (Optical Coherence Tomography) and NIR (Near Infrared Transillumination) products, and how OCT/NIR will impact the dental industry
      Read Full Article
    22. Optiphase Wins $1.1 Million NIST TIP Award

      VAN NUYS, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Optiphase, Inc. announced today that it has been selected to participate in a National Institute of Standards and Technology (NIST) Technology Innovation Program (TIP) to develop advanced sensing technologies that enable timely and detailed monitoring and inspection of the structural health of bridges, roadways and water systems that comprise a significant portion of the nation's public infrastructure.
      Read Full Article
      Mentions: Optiphase
    23. NIST Award Granted to Distributed Sensor Technologies, Inc. (DST) for Civil Infrastructure Fiber Optic Sensing System Development

      DST and Technology Partners RIO, Optiphase and UIC, Selected to Receive $4M. SANTA CLARA, Calif., Jan. 12, 2009 -- On January 6, 2009, NIST announced that it created nine awards under its newly formed Technology Innovation Program , for developing the next generation of structural health monitoring systems for large infrastructure elements.
      Read Full Article
      Mentions: Optiphase
    1-24 of 24
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks